Steve Riley

4.3k total citations
40 papers, 1.2k citations indexed

About

Steve Riley is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Steve Riley has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 13 papers in Cardiology and Cardiovascular Medicine and 5 papers in Oncology. Recurrent topics in Steve Riley's work include Cardiac electrophysiology and arrhythmias (11 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers) and Computational Drug Discovery Methods (5 papers). Steve Riley is often cited by papers focused on Cardiac electrophysiology and arrhythmias (11 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers) and Computational Drug Discovery Methods (5 papers). Steve Riley collaborates with scholars based in United States, United Kingdom and Sweden. Steve Riley's co-authors include Christine Garnett, Georg Ferber, Giampaolo Merlini, Daniel P. Judge, Marla B. Sultan, Philip T. Sager, Nenad Sarapa, James J. Keirns, Charles Benson and Börje Darpö and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, American Heart Journal and Clinical Pharmacology & Therapeutics.

In The Last Decade

Steve Riley

38 papers receiving 1.1k citations

Peers

Steve Riley
Jörg Täubel United Kingdom
Olivier Grenet Switzerland
Bo Jin China
Bin Zhao China
Andreas Leiherer Austria
Ikunosuke Sakurabayashi Japan
Irina Buhăescu Romania
Aram Adourian United States
Mary Donoghue United States
Sreeraj Macha United States
Jörg Täubel United Kingdom
Steve Riley
Citations per year, relative to Steve Riley Steve Riley (= 1×) peers Jörg Täubel

Countries citing papers authored by Steve Riley

Since Specialization
Citations

This map shows the geographic impact of Steve Riley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Riley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Riley more than expected).

Fields of papers citing papers by Steve Riley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Riley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Riley. The network helps show where Steve Riley may publish in the future.

Co-authorship network of co-authors of Steve Riley

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Riley. A scholar is included among the top collaborators of Steve Riley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Riley. Steve Riley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Powers, Evan T., et al.. (2025). Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic Benefits. Cardiology and Therapy. 14(3). 333–350. 2 indexed citations
2.
Rossman, Eric I., Todd Wisialowski, Hugo M. Vargas, et al.. (2023). Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As. Journal of Pharmacological and Toxicological Methods. 123. 107270–107270. 12 indexed citations
3.
4.
Riley, Steve, et al.. (2021). Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis. American Journal of Cardiovascular Drugs. 21(5). 535–543. 10 indexed citations
5.
Castaño, Adam, Marianna Bruno, Steve Riley, et al.. (2021). Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design Development and Therapy. Volume 15. 1225–1243. 31 indexed citations
6.
Damy, Thibaud, Pablo García‐Pavía, Mazen Hanna, et al.. (2020). Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial ( ATTR‐ACT ) and long‐term extension study. European Journal of Heart Failure. 23(2). 277–285. 124 indexed citations
7.
Purohit, Vivek S., Steve Riley, Huaming Tan, & William C. Ports. (2020). Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis. The Journal of Clinical Pharmacology. 60(10). 1344–1354. 6 indexed citations
8.
Tsamandouras, Nikolaos, Sridhar Duvvuri, & Steve Riley. (2019). Impact of Phase 1 study design on estimation of QT interval prolongation risk using exposure–response analysis. Journal of Pharmacokinetics and Pharmacodynamics. 46(6). 605–616. 1 indexed citations
9.
Darpö, Börje, Georg Ferber, James Li, et al.. (2019). Cardiac risk assessment based on early Phase I data and PK-QTc analysis is concordant with the outcome of thorough QTc trials: an assessment based on eleven drug candidates. Journal of Pharmacokinetics and Pharmacodynamics. 46(6). 617–626. 2 indexed citations
10.
Garnett, Christine, Peter L. Bonate, Qianyu Dang, et al.. (2017). Scientific white paper on concentration-QTc modeling. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 383–397. 170 indexed citations
11.
Ueckert, Sebastian, et al.. (2015). Modeling the Neuropsychiatric Inventory (NPI) - Strengths and Weaknesses of a Multidimensional Item Response Theory Approach. Journal of Pharmacokinetics and Pharmacodynamics. 42. 1 indexed citations
12.
Chater, Angel, Rhian Parham, Steve Riley, A. Hutchison, & Rob Horne. (2014). Profiling patient attitudes to phosphate binding medication: A route to personalising treatment and adherence support. Psychology and Health. 29(12). 1407–1420. 18 indexed citations
13.
14.
Cook, Jack, et al.. (2013). Quality-by-Design: Are We There Yet?. AAPS PharmSciTech. 15(1). 140–148. 20 indexed citations
15.
Darpö, Börje, Nenad Sarapa, Christine Garnett, et al.. (2013). The IQ‐CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”. Annals of Noninvasive Electrocardiology. 19(1). 70–81. 81 indexed citations
16.
Wonnacott, Alexa, Soma Meran, Gareth Roberts, et al.. (2012). Applying estimated glomerular filtration rate to an ageing population: are we in danger of becoming ageist?. European Journal of Internal Medicine. 23(8). 705–710. 1 indexed citations
17.
Meran, Soma, K. R. Don, Nikhil Shah, et al.. (2010). Impact of chronic kidney disease management in primary care. QJM. 104(1). 27–34. 10 indexed citations
18.
Parham, Rhian, et al.. (2009). PATIENTS’ SATISFACTION WITH INFORMATION ABOUT PHOSPHATE‐BINDING MEDICATION. Journal of Renal Care. 35(s1). 86–93. 12 indexed citations
19.
Riley, Steve, et al.. (2005). Protect Your Windows Network: From Perimeter to Data (Microsoft Technology). 2 indexed citations
20.
Riley, Steve, et al.. (2003). Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. BMJ. 327(7415). 608–609. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jörg Täubel Breakdown of academic impact, for papers by Olivier Grenet Breakdown of academic impact, for papers by Bo Jin Breakdown of academic impact, for papers by Bin Zhao Breakdown of academic impact, for papers by Andreas Leiherer Breakdown of academic impact, for papers by Ikunosuke Sakurabayashi Breakdown of academic impact, for papers by Irina Buhăescu Breakdown of academic impact, for papers by Aram Adourian Breakdown of academic impact, for papers by Mary Donoghue Breakdown of academic impact, for papers by Sreeraj Macha
Rankless by CCL
2026